Heron Therapeutics
HRTX
172 hedge funds and large institutions have $192M invested in Heron Therapeutics in 2025 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 57 increasing their positions, 52 reducing their positions, and 16 closing their positions.
19% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 16
10% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 52
1% more funds holding
Funds holding: 171 → 172 (+1)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
2.89% less ownership
Funds ownership: 86.17% → 83.28% (-2.9%)
29% less capital invested
Capital invested by funds: $272M → $192M (-$79.8M)
98% less call options, than puts
Call options by funds: $44K | Put options by funds: $2.68M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Clearline Capital
New York
|
+$14M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$6.74M |
| 3 |
Citigroup
New York
|
+$3.84M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$3.78M |
| 5 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$3.78M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$6.23M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$4.45M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$2.51M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.7M |
| 5 |
JFG
Jefferies Financial Group
New York
|
-$1.38M |
HRTX Hedge Fund Activity: Q3 2025 in Review
172 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q3 2025, worth a combined $192M — down 29% from $272M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new HRTX positions and 16 closed out — a net gain of 3 holders — while 57 added to existing stakes and 52 trimmed.
The largest buyer was Clearline Capital, adding an estimated $14M. The largest seller was AIGH Capital Management, exiting entirely with an estimated $6.23M sold.
- 172 institutional investors held Heron Therapeutics (HRTX) as of Q3 2025, up from 171 in Q2 2025.
- Funds reported $192M of Heron Therapeutics stock for Q3 2025, down 29% quarter-over-quarter.
- 19 funds opened new Heron Therapeutics positions in Q3 2025 and 16 closed out, a net change of +3 holders.
- The largest Heron Therapeutics buyer in Q3 2025 was Clearline Capital, an estimated $14M added.
- The largest Heron Therapeutics seller in Q3 2025 was AIGH Capital Management, an estimated $6.23M sold.
Based on aggregated 13F filings for Q3 2025.